BRPI9811031A - processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmídio. - Google Patents

processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmídio.

Info

Publication number
BRPI9811031A
BRPI9811031A BRPI9811031A BRPI9811031A BRPI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A
Authority
BR
Brazil
Prior art keywords
epo
preparing
human
human epo
gene
Prior art date
Application number
BRPI9811031A
Other languages
English (en)
Inventor
Anne Stern
Michael Brandt
Konrad Honold
Johannes Auer
Hans Koll
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9811031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BRPI9811031A publication Critical patent/BRPI9811031A/pt
Publication of BRPI9811031B1 publication Critical patent/BRPI9811031B1/pt
Publication of BRPI9811031B8 publication Critical patent/BRPI9811031B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

patente de invenção: <b>"preparação de eritropoietina mediante ativação de genes endógeno"<d>. a invenção refere-se a células humanas, que em virtude de uma ativação do gene epo humano endógeno estão em condição, de produzir epo em uma quantidade e pureza suficientes, para possibilitar uma preparação barata de epo humana como preparado farmacêutico. além disso, a invenção refere-se a um processo para preparar tais células produtoras de epo humana, construções de dna para a ativação do gene epo endógeno em células humanas, bem como processos para a produção em escala técnica de epo em células humanas. seqüência de ativação de gene:
BRPI9811031-4 1997-07-23 1998-07-22 processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmìdio. BRPI9811031B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PCT/EP1998/004590 WO1999005268A1 (de) 1997-07-23 1998-07-22 Herstellung von erythropoietin durch endogene genaktivierung

Publications (3)

Publication Number Publication Date
BRPI9811031A true BRPI9811031A (pt) 2000-08-08
BRPI9811031B1 BRPI9811031B1 (pt) 2011-10-04
BRPI9811031B8 BRPI9811031B8 (pt) 2021-07-06

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811031-4 BRPI9811031B8 (pt) 1997-07-23 1998-07-22 processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmìdio.

Country Status (13)

Country Link
EP (1) EP0986644B1 (pt)
JP (1) JP4541539B2 (pt)
CN (1) CN1151258C (pt)
AT (1) ATE341625T1 (pt)
AU (1) AU754619B2 (pt)
BR (1) BRPI9811031B8 (pt)
CA (1) CA2298015C (pt)
DE (1) DE59813758D1 (pt)
DK (1) DK0986644T3 (pt)
ES (1) ES2273434T3 (pt)
TR (1) TR200000175T2 (pt)
TW (1) TW574372B (pt)
WO (1) WO1999005268A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4220125B2 (ja) 1997-12-03 2009-02-04 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 高い比活性を有するエリスロポエチン
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002064085A2 (en) 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (ko) * 2001-10-30 2005-06-02 신풍제약주식회사 동물세포용 재조합 벡터 및 에리트로포이에틴을 대량으로 생산하기 위한 동물세포용 발현벡터
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BR0214557A (pt) 2001-11-28 2006-06-06 Ortho Mcneil Pharm Inc regime de dosagem de eritropoietina para o tratamento de anemia
US7129267B2 (en) 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
EP1520008B1 (en) 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
EA008670B1 (ru) 2003-05-09 2007-06-29 Круселл Холланд Б.В. Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
EP2134862A4 (en) * 2007-03-12 2011-04-20 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
EP2334699B1 (en) * 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
CN104059128B (zh) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659928B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659927B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
JPS62265992A (ja) * 1986-05-12 1987-11-18 Ajinomoto Co Inc ヒト細胞を用いる有用物質の製造方法
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (ja) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd 組換えヒトエリスロポエチンの精製方法
EP0747485B1 (en) * 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
ES2151463T5 (es) * 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
CA2298015A1 (en) 1999-02-04
JP2001511343A (ja) 2001-08-14
TR200000175T2 (tr) 2001-01-22
DE59813758D1 (de) 2006-11-16
BRPI9811031B1 (pt) 2011-10-04
AU754619B2 (en) 2002-11-21
CN1151258C (zh) 2004-05-26
BRPI9811031B8 (pt) 2021-07-06
JP4541539B2 (ja) 2010-09-08
CN1265143A (zh) 2000-08-30
TW574372B (en) 2004-02-01
ES2273434T3 (es) 2007-05-01
ATE341625T1 (de) 2006-10-15
EP0986644B1 (de) 2006-10-04
EP0986644A1 (de) 2000-03-22
WO1999005268A1 (de) 1999-02-04
DK0986644T3 (da) 2007-01-29
CA2298015C (en) 2015-01-27
AU8978698A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
BRPI9811031A (pt) processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmídio.
HUP9801697A2 (hu) Új protein és eljárás előállítására
EP0835099A4 (en) METHOD FOR CELL TRANSFECTION WITH LIPOSOMAL-ENCLOSED NUCLEIC ACIDS
EP1095158A4 (en) METHOD AND MATERIALS FOR THE PRODUCTION OF GLUCOSAMINE
ATE405644T1 (de) Verfahren zur herstellung und reinigung von erythropoietin
ATE78055T1 (de) Verfahren zur herstellung von proteinen und transformierten zellen und dna-konstruktionen zur korrektur von mankos und wirtszellen sowie deren herstellung und verwendung.
MX9304027A (es) Variante de al enzima lipasa y metodo para su produccion.
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
BR0012712B1 (pt) métodos de produção de l-aminoácidos aumentando-se o nadph celular.
MY161418A (en) Assembly of large nucleic acids
CY1105416T1 (el) Μεθοδος παρασκευης πολυαλκυλενιμινων που φερουν λειτουργικη ομαδα, συνθεσεις που τις πepιεχουν και οι χρησεις τους
DK163937C (da) Strukturelt gen, som koder for autentisk humant serumalbumin til ekspression i en ikke-human vaert, fremgangsmaade til fremstilling deraf, rekombinant-dna-molekyle indeholdende genet, vaertsorganisme transformeret dermed og fremgangsmaade til fremstilling af autentisk humant serumalbumin
BR112023008361A2 (pt) Variantes de glucoamilase e polinucleotídeos codificando as mesmas
BR9813099A (pt) Seleção positiva-negativa na recombinação homóloga
WO2002098455A8 (en) Production of recombinant human arylsulfatase a
WO2003006612A3 (en) Production of transduced hematopoietic progenitor cells
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
DE69939876D1 (de) Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren
WO1989009824A3 (en) Gene synthesis
ID26784A (id) Pembuatan sel-sel untuk memproduksi yang perhubungan dengan biologi
DK1019512T3 (da) Fremgangsmåde til fremstilling af forgrenede fedtsyrer ved hjælp af genetisk modificerede planter
AR016774A1 (es) Identificacion de lineas celulares humanas para la produccion de proteinas humanas por activacion genica endogena
DE50110507D1 (de) Verfahren in vitro zum einbringen von nukleinsäure in eine zelle (transfektion) mittels calciumphosphat
TR200700154A2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
WO1997045547A3 (de) Lokalisierter zelltod in pflanzen

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.07.2018